Search Results 1-10 of 16569 for ������������KA���:ZA31���24������ ���������������������������������

  1. 24-Hydroxylase Deficiency and CYP24A1 Mutation Patient Registry - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  2. DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma - Mayo Clinic

    This study is being conducted to examine survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with ...

  3. Ratio of 25(OH)D-to-24,25(OH)2D: A new test to confirm 24-hydroxylase (CYP24A1) deficiency as the cause of hypercalcemia - Mayo Clinic

    Researchers found that the ratio of 25(OH)D-to-24,25(OH)2D is necessary to estimate the calculation of vitamin D 24-hydroxylase enzyme activity to confirm ...

  4. Publications - Sujay A. Vora, M.D. - Mayo Clinic

    ... KA. Intraoperative Radiation Therapy (IORT) in ... 24-00665R1) The Lancet Oncology. 2024. Routman DM ... 2024 Mar 12; 24(1):332. View PubMed; Zhang L ...

  5. Mayo Clinic 2024 Annual Security Report - Minnesota campus

    24. Risk Reduction Strategies ... 24. Safe and Positive Options for Bystander Intervention ...

  6. Breast Imaging Scholarly Activity

    National/Regional 3/26/2018 1/24/2018. Pregnancy ... Presentation - National/Regional n/a 7/24/2017 ... Robinson KA, Kriegshauser JS, Dahiya N, Young SW, Czaplicki ...

  7. Publications - Katie A. Young, M.D. - Mayo Clinic

    Young KA, Rodeheffer RJ, Bird JG, Miranda WR ... 2024 Dec 17; 13 (24):e038965 Epub 2024 Dec 14 ... 2022 Oct; 35 (10):1055-1063 Epub 2022 June 24. View ...

  8. Dasatinib And Quercetin With CAR T Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

    Rochester, Minnesota: 24-002915. NCT ID: NCT06940297. Sponsor Protocol Number: MC240801. About this study. This phase II trial tests how well giving dasatinib ...

  9. A Trial of the Effectiveness, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides difficile Infection (PRISM4) - Mayo Clinic

    ... 24 visit. Males (as assigned at birth) must fulfill the following criteria ... difficile-related diarrhea within 8 weeks after receiving CP101 or placebo in Part ...

  10. Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Systemic Sclerosis - Mayo Clinic

    Serum creatinine must be stable (with no increases ≥ 20%) for a minimum of 24 weeks post-renal crisis at the time of the screening visit. Cardiac ...